Founder, Vatera Healthcare Partners
Mr. Jaharis is co-founder of Arisaph Pharmaceuticals Inc. and has served as a Director of the company since 2005. The Jaharis Family has committed the majority of the firm’s funding since inception. Mr. Jaharis also co-founded Kos Pharmaceuticals, Inc., which was acquired by Abbott Laboratories in December 2006 for over $4 billion. At Kos, Mr. Jaharis committed approximately $200 million of funding to develop and commercialize Niaspan® the most potent, patient-friendly drug that raises HDL cholesterol.
Prior to Kos, Mr. Jaharis was the President and Chief Executive Officer of Key Pharmaceuticals from 1972 until its merger with Schering-Plough Corporation in 1986. Mr. Jaharis developed and executed the strategies that allowed Key to grow from only a few small cough and cold products that aggregated less than $2 million in sales to $200 million in worldwide sales by 1986, including Theo-Dur, which was the best-selling asthma product in the U.S. at that time, and Nitro-Dur, a major advance in angina therapy. Prior to Key, from 1961 to 1972, Mr. Jaharis was with Miles Laboratories, last serving as Vice President of the Ethical Drug Division. Mr. Jaharis received his B.A. from Carroll College and his law degree from DePaul University.
Mr. Jaharis also serves as Trustee Emeritus of Tufts University in Boston; Chairman of the Board of Overseers for the School of Medicine, Tufts University; Member of the Columbia University Medical Center Board of Visitors; Member of the Board of Overseers of the Weill Cornell Medical College and Graduate School of Medical Sciences; Director of The Onassis Public Benefit Foundation (USA); and Vice Chairman of the Greek Orthodox Archdiocese of America.